Trends in palliative care interventions among patients with advanced bladder, prostate, or kidney cancer: A retrospective cohort study
Patrick M. Lec(University of California, Los Angeles), Karim Chamie(University of California, Los Angeles), Vishnukamal Golla(University of California, Los Angeles), Alexandra Drakaki(University of California, Los Angeles), Andrew T. Lenis(Memorial Sloan Kettering Cancer Center), Wayne Brisbane(University of California, Los Angeles), Jonathan Bergman(Los Angeles County Department of Health Services), Vidit Sharma(University of California, Los Angeles), Kiran Gollapudi(UCLA Medical Center), Jeremy Blumberg(UCLA Medical Center)
Cited by 23
Related Papers
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
An overview of kidney stone imaging techniques
|Nature Reviews Urology|2016|389
An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results
|Urologic Oncology Seminars and Original Investigations|2017|250
Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling
|European Urology|2022|169